AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for ATP-binding cassette sub-family G member 8

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9H221

UPID:

ABCG8_HUMAN

Alternative names:

Sterolin-2

Alternative UPACC:

Q9H221; Q53QN8

Background:

ATP-binding cassette sub-family G member 8 (ABCG8), also known as Sterolin-2, forms a crucial heterodimer with ABCG5. This partnership is pivotal for the Mg(2+)- and ATP-dependent transport of sterols across cell membranes, playing a vital role in dietary cholesterol management and sterol excretion by the liver into bile. The ABCG5/ABCG8 complex's ability to regulate sterol homeostasis underscores its importance in cellular lipid processes.

Therapeutic significance:

The involvement of ABCG8 in gallbladder disease 4 and sitosterolemia 1, conditions characterized by cholesterol and sterol metabolism disorders, highlights its potential as a therapeutic target. Understanding the role of ABCG8 could open doors to potential therapeutic strategies, offering hope for patients suffering from these metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.